SARM
SLU-PP-332
SaveAn ERRα/ERRγ agonist developed at Washington University, studied as an exercise mimetic that activates endurance-related gene programs without androgen receptor binding. Not a true SARM.
Quick verdict
A novel exercise-mimetic compound with promising rodent data. Entirely preclinical and mechanistically distinct from SARMs.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Rodent studies published in 2023 showed increased fatigue resistance, enhanced oxidative muscle fiber content, and reduced fat mass without changes in food intake. No human data.
Benefits
- Enhanced endurance capacity in mouse models
- Reduced fat mass without affecting food intake in animals
- Increased oxidative muscle fiber proportion preclinically
Dosage notes
No human dosing data. Rodent studies used intraperitoneal injection.
Side effects
- Unknown in humans
Who should be cautious
Not approved for human use. No human pharmacokinetic or safety data. Mechanism is distinct from traditional SARMs.
What this page cannot tell you
Exercise-mimetic claims are based on rodent treadmill performance. Human translation is entirely speculative.
Leaderboard scores
- Energy25
- Weight loss20
- Muscle20
Write a review
Sign in to write a review.